Evidence map›Paper›PMID 38559245›Full record

ArticlebioRxiv : the preprint server for biology2024

Inhibition of Acyl-CoA Synthetase Long Chain Isozymes Decreases Multiple Myeloma Cell Proliferation and Causes Mitochondrial Dysfunction.

Connor S Murphy, Victoria E DeMambro, Samaa Fadel, Heather Fairfield, Carlos A Garter, Princess Rodriguez, Ya-Wei Qiang, Calvin P H Vary, Michaela R Reagan

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Connor S MurphyCenter for Molecular Medicine, MaineHealth Institute for Research, Scarborough, ME, USA.ORCID 0000-0001-6533-3920
Victoria E DeMambroCenter for Molecular Medicine, MaineHealth Institute for Research, Scarborough, ME, USA.
Samaa FadelCenter for Molecular Medicine, MaineHealth Institute for Research, Scarborough, ME, USA.
Heather FairfieldCenter for Molecular Medicine, MaineHealth Institute for Research, Scarborough, ME, USA.ORCID 0000-0002-8852-2254
Carlos A GarterCenter for Molecular Medicine, MaineHealth Institute for Research, Scarborough, ME, USA.
Princess RodriguezUniversity of Vermont, Burlington, VT, USA.
Ya-Wei QiangCenter for Molecular Medicine, MaineHealth Institute for Research, Scarborough, ME, USA.ORCID 0000-0002-2479-1412
Calvin P H VaryCenter for Molecular Medicine, MaineHealth Institute for Research, Scarborough, ME, USA.
Michaela R ReaganCenter for Molecular Medicine, MaineHealth Institute for Research, Scarborough, ME, USA.ORCID 0000-0003-2884-6481
MaineHealth · USTufts University · USUniversity of New England · USUniversity of Vermont · US

Funding

Understanding Factors Influencing COVID-19 Testing and Vaccination in Immigrant Low-income and Homeless Populations and Testing Targeted InterventionsU54GM115516 · NIGMS · MAINEHEALTH · PI CLIFFORD JAMES ROSEN, Gary S. Stein · 2017 to 2026
$51.6M
The role of night shift work in metabolic disorders during and after pregnancyP20GM121301 · NIGMS · MAINEHEALTH · PI Calvin Pardee Hull Vary · 2017 to 2026
$25.1M
Interdisciplinary Study of Marrow Adiposity, Mineral Metabolism & Energy BalanceR24DK092759 · NIDDK · MAINEHEALTH · PI HOROWITZ, MARK C, MACDOUGALD, ORMOND A · 2011 to 2019
$13.0M
Defining the Roles of Bone Marrow Adipocytes and FABP4/5 Signaling in Multiple Myeloma Drug Resistance - Diversity SupplementR37CA245330 · NCI · MAINEHEALTH · PI REAGAN, MICHAELA R. · 2020 to 2025
$2.8M
Research Specialist Support for Defining the Roles of Bone Marrow Adipocytes and FABP4/5 Signaling in Multiple MyelomaR50CA265331 · NCI · MAINEHEALTH · PI Heather F Campbell · 2022 to 2026
$498k
Lipid Metabolism-driven Drug Resistance in Multiple MyelomaF31CA257695 · NCI · MAINEHEALTH · PI MURPHY, CONNOR · 2021 to 2023
$96k
NCI NIH HHS F31 CA257695NCI NIH HHS R37 CA245330NCI NIH HHS R50 CA265331NIDDK NIH HHS R24 DK092759NIGMS NIH HHS P20 GM121301NIGMS NIH HHS U54 GM115516
6 · The paper itself

Abstract

Multiple myeloma (MM) is an incurable cancer of plasma cells with a 5-year survival rate of 59%. Dysregulation of fatty acid (FA) metabolism is associated with MM development and progression; however, the underlying mechanisms remain unclear. Acyl-CoA synthetase long-chain family members (ACSLs) convert free long-chain fatty acids into fatty acyl-CoA esters and play key roles in catabolic and anabolic fatty acid metabolism. The Cancer Dependency Map data suggested that ACSL3 and ACSL4 were among the top 25% Hallmark Fatty Acid Metabolism genes that support MM fitness. Here, we show that inhibition of ACSLs in human myeloma cell lines using the pharmacological inhibitor Triascin C (TriC) causes apoptosis and decreases proliferation in a dose- and time-dependent manner. RNA-seq of MM.1S cells treated with TriC for 24 h showed a significant enrichment in apoptosis, ferroptosis, and ER stress. Proteomics of MM.1S cells treated with TriC for 48 h revealed that mitochondrial dysfunction and oxidative phosphorylation were significantly enriched pathways of interest, consistent with our observations of decreased mitochondrial membrane potential and increased mitochondrial superoxide levels. Interestingly, MM.1S cells treated with TriC for 24 h also showed decreased mitochondrial ATP production rates and overall lower cellular respiration.

Indexed as

ACSLhematological malignanciesmultiple myelomaTriascin C

Identifiers

PMID38559245
PMCPMC10979990
OpenAlexW4392860324

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.